GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » TalkMed Group Ltd (SGX:5G3) » Definitions » Valuation Rank

TalkMed Group (SGX:5G3) Valuation Rank


View and export this data going back to 2014. Start your Free Trial

What is TalkMed Group Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

TalkMed Group Valuation Rank Related Terms

Thank you for viewing the detailed overview of TalkMed Group's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

TalkMed Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » TalkMed Group Ltd (SGX:5G3) » Definitions » Valuation Rank
Comparable Companies
SGX:QC7 SGX:40T SGX:5WA SGX:EHG SGX:9G2 SGX:OTX SGX:MIJ SGX:NPL SGX:1D4 SGX:FRQ HCA SAU:4013 XTER:FRE SZSE:300015 XTER:FME XKLS:5225 THC BOM:543220 UHS DVA
Traded in Other Exchanges
N/A
Address
3 Mount Elizabeth, Mount Elizabeth Hospital Level 2, Singapore, SGP, 228510
Website
https://www.talkmed.com.sg
TalkMed Group Ltd operates as an investment holding company. It is a provider of medical oncology, stem cell transplants and palliative care services, serving patients in Singapore and the region. Outside Singapore, the Group operates in Vietnam, Hong Kong and the People's Republic of China. The activities of the company are the provision of medical oncology services and palliative care healthcare services in Singapore. It is organized into two reportable operating segments, Oncology Services and Cellular and gene therapy-related products and services. The company has operational footprints across Singapore, China and Hong Kong, Australia, Vietnam and others of which Singapore contributes the vast majority of total revenue. It generates maximum revenue from the Oncology services segment.